- Applied DNA Sciences (APDN, Financial) regains compliance with Nasdaq listing requirements.
- Minimum bid price requirement of $1.00 per share successfully met.
- Scheduled Nasdaq delisting hearing on July 15, 2025, has been cancelled.
Applied DNA Sciences, Inc. (APDN), a pioneer in PCR-based DNA technologies, announced it has regained compliance with Nasdaq's listing requirements as of July 2, 2025. This compliance was achieved by meeting the minimum bid price of $1.00 per share, as mandated by Nasdaq's Listing Rule 5550(a)(2).
The company received confirmation from Nasdaq, negating the necessity for the previously scheduled hearing before the Nasdaq Hearings Panel set for July 15, 2025. With this development, APDN's securities will continue to be listed and actively traded on the Nasdaq Capital Market without any interruptions.
Applied DNA Sciences, known for its expertise in DNA production through its LineaRx Inc. subsidiary, focuses on the advancement of nucleic acid-based therapies via its LineaDNA and LineaIVT platforms. This milestone solidifies its market presence, ensuring continued investor confidence and operational stability.
For more information, visit the company's website or follow them on their social media platforms. Investors and stakeholders can remain assured of the company's forward momentum and strategic direction in the biotechnology sector.
